Download - Sustained Release Formulations
![Page 1: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/1.jpg)
1
SUSTAINED RELEASE FORMULATIONS
Prof. Dr. Basavaraj K. Nanjwade M. Pharm., Ph. DDepartment of PharmaceuticsKLE University’s College of Pharmacy, Belgaum- 590010, Karnataka, IndiaCell No: 0091 9742431000E-mail: [email protected]
![Page 2: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/2.jpg)
2
IntroductionIntroduction
ConceptConcept
Advantages and disadvantagesAdvantages and disadvantages
Physicochemical propertiesPhysicochemical properties
Biological propertiesBiological properties
![Page 3: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/3.jpg)
3
The period between 1950 to 1970 is considered as period of Sustained drug release.
The main AIM of preparing sustained release formulation’s was intended to modify and improve the drug performance by
Increasing the duration of drug action.
Decreasing the frequency of dosing.
Decreasing the required dose employed.
Providing uniform drug delivery.
![Page 4: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/4.jpg)
4
DEFINITIONS:-
SRF’s describes the slow release of a drug substance from a dosage form to maintain therapeutic response for extended period (8-12hrs)of time. Time depends on the dosage form. In oral form it is in hours, and in parenteral’s it is in days and months. Ex: Aspirin SR, Dextrim SR.
Controlled release dosage form: In this the rate or speed at which the drug is released is controlled.
Ex: Adalat CR (Nifidipine), Dynacirc CR (Isradipine.)
![Page 5: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/5.jpg)
5
The of SRDF’s is to obtain Zero order release from the dosage form.
Zero order release is a release which is independent of the amount of drug present in the dosage form.
Usually SRDF’s do not follow zero order release but they try to mimic zero order release by releasing the drug in a slow first order fashion.
Pharmacological action is seen as long as the drug is in therapeutic range, problems occur when drug concentration is above/below therapeutic range.
![Page 6: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/6.jpg)
6
PARENTRALS
Pellets Solutions
Suspensions
Repeat action
Mixed release granules
Multilayer granules
Porous inert carrier
Osmotic system
Ion exchange resin
Slightly soluble salts complexes
ORAL
suspensions
Capsules
Tablets
Slow release
![Page 7: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/7.jpg)
7
Improved patient compliance: Less frequent dosing Allows whole day coverage.
Decreased local and systemic side effects. Decreased GIT irritation. Decreased local inflammation.
Better drug utilisation. Decreased total amount of drug used. Minimum drug accumulation on chronic dosing.
Improved efficiency in treatment. Uniform blood and plasma concentration. Decreased fluctuation in drug level i.e uniform pharmacological
response. Increased bioavailability of some drugs Special effects: SR Aspirin gives symptomatic relief in Arthritis
after waking Economy
![Page 8: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/8.jpg)
8
DOSE DUMPING :Increase quantity of drug release causes
dumping of drug which in turn leads to toxicity.
REDUCED POTENTIAL FOR ACCURATE DOSE
ADJUSTMENT: Administrating a fraction of drug is not possible.
NEED FOR ADDITIONAL PATIENT EDUCATION:
“Do not Crush or Chew the dosage unit”.
“ Tablet residue may appear in stools”.
STABILITY PROBLEMS: The complexity of SRF’s will lead to
stability problem.REDUCTION IN SYSTEMIC AVAILABILITY: Example
Theophylline, Procainamide and vitamin combinations.
![Page 9: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/9.jpg)
9
Retrieval of the drug is difficult in case of toxicity / poisoning /
hypersensitive reaction.
Higher cost of the formulation.
Half life: Drugs having shorter half life (less than one hour) and
drugs having longer half life (More than twelve hrs) cannot be
formulated as SRDF’s.
If a dosage form contains more than 500mgs., of active
ingredient formulation of SRDF’s is difficult.
If CRDF is required (With New polymers) cost of government
approval is very high.
![Page 10: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/10.jpg)
10
DRUG PROPERTIES: Stability, solubility, partition coefficient
and protein binding are to be considered.
ROUTE OF DRUG DELIVERY: Area of the body where drugs
are applied or administered play a vital role.
TARGET SITES: To minimize side effects, its desired to
maximize the fraction of dose applied.
ACUTE OR CHRONIC DOSING: Cure, Control and length of
drug therapy must be considered.
THE DISEASE: Pathological conditions play a significant role.
THE PATIENT: Ambulatory/ bedridden, young or old, etc.,
must be considered.
![Page 11: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/11.jpg)
11
AQUEOUS SOLUBILITY & pKa
PARTITION COEFFICIENT
DRUG STABILITY
PROTEIN BINDING
MOLECULAR SIZE & DIFFUSIVITY
DOSE SIZE
![Page 12: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/12.jpg)
12
AQUEOUS SOLUBILITY
For a drug to be absorbed, it must first dissolve in the
aqueous phase surrounding the site of administration.
AqS of a drug influences its dissolution rate which in turn
establishes its concentration in solution.
Dissolution rate is related to AqS solubility as shown by
Noyes Whitney equation under sink condition( CGIT»C)
dc/ dt= KD ACS
dc/ dt- dissolution rate
KD - dissolution rate constant
A- Total surface area of drug particles.
CS- Aqueous saturation solubility.
![Page 13: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/13.jpg)
13
Drugs with low aqueous solubility have low dissolution rate and
have oral bioavailability problems. E.g.: Tetracycline.
Drugs with high aqueous solubility are undesirable to formulate
SRDF’s. E.g.: Aspirin.
![Page 14: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/14.jpg)
14
The aqueous solubility of weak acids & weak bases is governed by the pKa of the compound and pH of the medium.
FOR WEAK ACID
St = So(1+Ka\[H ] =So(1+10pH-pKa)
St – Total solubility of the weak acid So – Solubility of the un-ionized form Ka – Acid dissociation constant H - Hydrogen ion concentration
Weakly acidic drug exist as unionized form in the stomach
absorption is favored by acidic medium
![Page 15: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/15.jpg)
15
FOR WEAK BASES:
St = So(1+[H ] \Ka) =So(1+pKa-pH)
St – Total solubility of both conjugate and free base form of weak base.
So– Solubility of the free base.
Weakly basic drug exists as ionized form in the stomach
hence absorption of this type is poor in this medium.
![Page 16: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/16.jpg)
16
PARTITION COEFFICIENT
Between the time of drug administration & elimination it diffuse
through several membranes ( Lipid barrier’s)
Oil/Water partition coefficient plays a major role in evaluating
the drug penetration.
K=Co/Cs
Where..
Co= Equilibrium concentration in organic phase.
Cs= Equilibrium concentration in aqueous phase.
Drugs with extremely high partition coefficient are very oil soluble and penetrates in to various membranes very easily.
![Page 17: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/17.jpg)
17
Contd……….. The relationship between tissue penetration and partition
coefficient for the drug is known as Hansch Correlation.
Log K
Log
act
ivit
y
The activity of the drug is a function of its ability to cross
membranes and interact with receptors. The more
effectively the drug crosses the membrane the greater is the
activity
![Page 18: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/18.jpg)
18
Contd……..
There is an optimum partition coefficient for a drug in which it
permeates membrane effectively and shows greater activity.
Partition coefficient with higher or lower than the optimum are
poorer candidates for the formulation
Unionized water soluble are highly absorbed from the intestine
and lipid soluble drugs are absorbed from the tissue.
![Page 19: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/19.jpg)
19
Contd……..
Values of partition coefficient below optimum result in the
decreased lipid solubility and remain localized in the first
aqueous phase it contacts.
Values larger than the optimum , result in poor aqueous
solubility but enhanced lipid solubility and the drug will not
partition out of the lipid membrane once it gets in.
![Page 20: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/20.jpg)
20
Solid state undergoes degradation at much slower rate than
in the suspension or solution etc..
Drugs stable in stomach gets released in stomach and which
are unstable gets released in intestine.
Drugs with stability problems in any particular area of G.I.T
are less suitable for the formulation.
Drugs may be protected from enzymatic degradation by
incorporation in to a polymeric matrix.
![Page 21: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/21.jpg)
21
Drug binding to plasma proteins (albumins) & resulting retention of the drug in the vascular space.
Drug-protein complex can serve as a reservoir in vascular
space.
Main forces for binding are Vander Waal forces, hydrogen bonding , electrostatic forces.
Charged compounds has greater tendency to bind proteins than uncharged ones.
Extensive binding of plasma proteins results in longer half-life of elimination for the drug
E.x..95% binding in Amitriptyline , diazepam , diazepoxide.
![Page 22: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/22.jpg)
22
The ability of the drug to diffuse through a membrane is called diffusivity (Diffusion coefficient). It is the function of its molecular size (molecular weight).
In most polymers it is possible to relate log D
to some function of molecular size as,
Log D = -Svlog V + Kv = -Smlog M+ Km
![Page 23: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/23.jpg)
23
Contd...,
V – Molecular volume.M – Molecular weight.Sv, Sm, Kv & Km are constants
The value of D is related to the size and shape of the cavities, as well as the drugs.
The drugs with high molecular weight show very slow kinetics.
![Page 24: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/24.jpg)
24
For those drugs requiring large conventional doses, the
volume of sustained dose may be too large to be practical.
The compounds that require large dose are given in
multiple amounts or formulated into liquid systems.
For oral route the volume of product is limited by patients.
For IM,IV or SC routes its tolerated.
![Page 25: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/25.jpg)
25
ABSORPTIONDISTRIBUTIONMETABOLISMELIMINATION & HALF LIFESIDE EFFECTS & MARGIN OF SAFETYROLE OF DISEASED STATEROLE OF CIRCADIAN RHYTHM
![Page 26: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/26.jpg)
26
The release of a drug from a dosage form is important than
its absorption.
The reason of poor absorption are poor water solubility, low
partition coefficient, acid hydrolysis and metabolism.
For SRDF’s rate of release is much slower than the rate
of absorption.
Transit time of drug is between 9-12hrs.
Maximum absorption half-life should be 3-4hr.
![Page 27: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/27.jpg)
27
Continued..
Low density pellets, capsules or tablets are formulated which
float on top of gastric juice and delay their transfer out of
stomach e.g. PABA
GI retention for drugs with poor absorption can be increased
by enhancers.
Bioadhesive materials is made which has high affinity to the
mucin coat.
A drug that is slowly absorbed is poor candidate for SRDF
eg.,Gentamycin, Hexamethonium
![Page 28: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/28.jpg)
28
Distribution of drugs in to vascular & extra vascular spaces is an important factor.
Apparent volume of distribution & drug concentration in tissue to that of plasma at steady state are important parameters for distribution. It is called T\P ratio.
Calculation of this distribution is mainly based on one compartment pharmacokinetic models.
It is given by.. V= Dose\CoCo–Initial concentration immediately after i.v bolus injection
![Page 29: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/29.jpg)
29
For two compartment models, the total volume of distribution is given by the apparent volume of the distribution at steady state
Vss = (1+K12\K21)V1Where. V1 - Volume of the central compartment K12-Rate constant for distribution of the drug from central compartment to peripheral K21 - Peripheral to the central compartment blood or plasma to the total volume.
![Page 30: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/30.jpg)
30
Metabolic conversion of drug to another chemical form.
Factors associated with metabolism are;
Ability of drug to induce or inhibit enzyme synthesis. This
results in fluctuating drug blood level with chronic dosing.
Fluctuating drug blood level due to intestinal metabolism or
through a hepatic first pass effect. Ex.., intestinal metabolism
upon oral dosing are hydralazine , salicylamide , nitroglycerine.
![Page 31: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/31.jpg)
31
Rate of elimination of the drug is described quantitatively by its biological half life i.e.. T1/2.
The half life of the drug is related to its apparent volume of distribution and its systemic clearance.
t1/2 = 0.693V/CLs = 0.693 AUC/dose
![Page 32: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/32.jpg)
32
Contd...
A drug with shorter half life requires frequent dosing.
Drugs with half life 2hr should not be used ,since such system
requires unexpectedly large release rate and large doses.
E.x.., Ampicillin , Cephalosporin
Drugs with half life greater than 8 hrs should not be used,
formulation of such drugs is unnecessary.
E.x.., Diazepam, Digitoxin , Digoxin
![Page 33: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/33.jpg)
33
SRDF is useful in minimizing the side effects of the drug.Slow release potassium – SR of potassium to prevent gastric irritation. Timed release of aspirin – to prevent gastric irritation.
Measure of margin of safety of the drug is THERAPEUTIC INDEX(TI). TI = TD50\ED50
TD50 = median toxic dose ED50 = median effective dose.
For potent drugs TI value is small. Larger the value of TI safer the drug.Drugs with small value of TI are poor candidates for the formulation.A drug is considered to be relatively safe if TI exceeds 10.Some drugs of TI less than 10 are Digitoxin, Digoxin and Phenobarbitone.
![Page 34: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/34.jpg)
34
Different methods used are..
BASED ON DRUG MODIFICATION.
BASED ON DOSAGE FORM MODIFICATION.
![Page 35: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/35.jpg)
35
BASED ON DRUG MODIFICATION:
COMPLEX FORMATION
DRUG-ADSORBATE PREPARATION .
PRO DRUG SYNTHESIS.
ION EXCHANGE RESINS.
![Page 36: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/36.jpg)
36
Complex formation:
The rate of dissolution of solid complex in biological fluids
and rate of dissociation of complex in the solution are considered
and they depend upon pH and composition of gastric and
intestinal fluids.
Drug-adsorbate preparation:
In this product is insoluble. Drug availability is determined
by rate of disabsorption.
Pro drug synthesis:
They are inactive and need enzymatic hydrolysis for
regeneration. Solubility, absorption rate of prodrug must be lower
than parent drug.
![Page 37: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/37.jpg)
37
Ion exchange resins:
They are water insoluble, cross linked polymers
containing salt forming groups. The drug is bound to the resin
by using chromatographic column or by prolonged contact.
Drug release from this complex depends on pH &
property of resin. Drug that is attached to the resin is released
by exchanging with the ions present in the GIT.
Resin+ -Drug- +X- Resin+- X- + Drug-
Example: Biphetamine.
![Page 38: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/38.jpg)
38
BASED ON DOSAGE FORM MODIFICATION.
Microencapsulation:
It’s a process in which tiny particles are surrounded by
uniform coating (microcapsule) or held in a matrix of polymer
(microsphere.) Spray drying is used which involves rapid
evaporation of the solvent from the drug surface.
Barrier coating:
In this one quarter of the granules are in non sustained
form for sudden drug release, remaining part are coated for
sustained release. Both these granules are filled in hard gelatin
capsule or compressed in a tablet, and the release mechanism is
by diffusion. Coating material used are fats, waxes.
![Page 39: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/39.jpg)
39
Matrix embedding: Drug is dispersed in a matrix of retardant material which may be encapsulated or compressed in a tablet.
![Page 40: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/40.jpg)
40
Name Marketer Dosage form IndicationCarbotrol
Glucotrol Xl
Adderall XR
Procardia Xl
Ortho Evra
Dura gesic
Shri Us
Pfizer
Shri US
Pfizer
Ortho – Mcneil
Janssen
Oral capsule
Oral TabletOral Tablet
Oral Capsule Oral Capsule
Oral TabletOral Tablet
Trans Dermal PatchTrans Dermal Patch
Trans Dermal PatchTrans Dermal Patch
Epilepsy
Hyperglycaemia
ADHD
Angina / Hypertension
Contraceptive
Chronic pain
![Page 41: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/41.jpg)
41
1) Text book of Sustained release dosage form by Y.S.Robinson,
Decker Series.
2) Controlled release dosage form by Y.W.Chien.
3) Ansel’s Pharmaceutical Dosage forms and Drug delivery
Systems.
4) Tutorial Pharmacy by Cooper and Gunns.
5) Remington’s Pharmaceutical Sciences
6) Text book of Pharmaceutics by Bentley and Drivers.
7) www.google.co.in (CRDF design- google book result- cherng-
jukin).
8) Text book of Pharmaceutical Sciences by Aulton.
![Page 42: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/42.jpg)
42
Queries
![Page 43: Sustained Release Formulations](https://reader038.vdocuments.mx/reader038/viewer/2022102507/5449f814af79592a1c8b45bf/html5/thumbnails/43.jpg)
43